Article
Public, Environmental & Occupational Health
A. Vallee, A. Chan-Hew-Wai, B. Bonan, P. Lesprit, F. Parquin, E. Catherinot, J. Choucair, D. Billard, C. Amiel-Taieb, E. Camps, C. Cerf, D. Zucman, E. Fourn
Summary: A study conducted in Foch Hospital, France, on 451 healthcare workers who received the AstraZeneca vaccine found that 60.8% reported multiple adverse effects, with fever, fatigue, and muscle pain being the main symptoms. Despite some European countries temporarily suspending the vaccine due to safety concerns, the benefit of vaccination remains evident.
Letter
Dermatology
F. Hali, A. Kerouach, H. Alatawna, S. Chiheb, H. Lakhdar
Summary: This case suggests a possible causal association between the COVID-19 vaccine and linear IgA bullous dermatosis, highlighting the importance of monitoring for immune-mediated bullous diseases following vaccination.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2022)
Article
Dermatology
Imran Majid, Samia Mearaj
Summary: Vaccination for COVID-19 has led to various cutaneous and extracutaneous adverse effects, with local injection-site reactions being the most common. This study reports a case of Sweet syndrome in an elderly female following the first dose of the Oxford-AstraZeneca COVID-19 vaccine (AZD1222).
DERMATOLOGIC THERAPY
(2021)
Article
Public, Environmental & Occupational Health
Nguyen Van Vinh Chau, Lam Anh Nguyet, Nguyen Thanh Truong, Le Mau Toan, Nguyen Thanh Dung, Le Manh Hung, Mai Thanh Nhan, Dinh Nguyen Huy Man, Nghiem My Ngoc, Huynh Phuong Thao, Tran Nguyen Hoang Tu, Huynh Kim Mai, Do Thai Hung, Nguyen Thi Han Ny, Le Kim Thanh, Nguyen To Anh, Nguyen Thi Thu Hong, Le Nguyen Truc Nhu, Lam Minh Yen, Marc Choisy, Tran Tan Thanh, Guy Thwaites, Le Van Tan
Summary: This study examined the immunogenicity of the Oxford-AstraZeneca vaccine in healthcare workers in Vietnam. The results showed that the proportion of participants with detectable neutralizing antibodies increased after each dose, and age and gender had an impact on the levels of neutralizing antibodies. However, these associations were less significant at day 28 and were not observable after the second dose.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
(2022)
Article
Infectious Diseases
David W. Eyre, Sheila F. Lumley, Jia Wei, Stuart Cox, Tim James, Anita Justice, Gerald Jesuthasan, Denise O'Donnell, Alison Howarth, Stephanie B. Hatch, Brian D. Marsden, E. Yvonne Jones, David Stuart, Daniel Ebner, Sarah Hoosdally, Derrick W. Crook, Tim E. A. Peto, Timothy M. Walker, Nicole E. Stoesser, Philippa C. Matthews, Koen B. Pouwels, A. Sarah Walker, Katie Jeffery
Summary: The study found that nearly all healthcare workers develop detectable anti-spike antibodies after receiving the Pfizer-BioNTech or Oxford-AstraZeneca vaccines. Those with prior infection and younger age were more likely to test seropositive after the first dose.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Medicine, General & Internal
Welder Zamoner, Julia Baldon Scardini, Bruna Jordana De Dio, Amanda de Melo Marques, Vanessa dos Santos Silva, Aline Lutz Garcia, Daniela Cristina dos Santos, Rosa Marlene Viero
Summary: This article presents a case of rapidly progressive glomerulonephritis following the Oxford-AstraZeneca COVID-19 vaccine in a 58-year-old female patient. The patient experienced symptoms such as fatigue, anemia, and abnormal urine after vaccination, and her kidney function deteriorated. With appropriate treatment, the patient's condition is currently stable.
FRONTIERS IN MEDICINE
(2022)
Article
Immunology
Majid A. Darraj, Hesham M. Al-Mekhlafi
Summary: This study investigated the short-term side-effects reported by healthcare workers in Saudi Arabia after receiving the first dose of the Oxford/AstraZeneca COVID-19 vaccine. The most commonly reported side-effects included injection site pain and redness, fever, whole-body pain/fatigue, and headache.
Article
Public, Environmental & Occupational Health
Elias Ali Yesuf, Abanoub Riad, Ahmad Sofi-Mahmudi, Morankar Sudhakar, Addisalem Mekonnen, Selamawit Endalkachew, Feyissa Mama, Semira Muhidin, Bethelhem Ayele, Mohammed Yahya, Abduselam Usman, Jemal Abafita, Miloslav Klugar
Summary: This study examined the prevalence and predictors of self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine in Ethiopia. The results showed a modest prevalence of side effects, mostly occurring within the first three days.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Immunology
Michael Bang Petersen, Frederik Jorgensen, Marie Fly Lindholt
Summary: The AstraZeneca vaccine was suspended in several European countries, leading to decreased public vaccine acceptance. The study emphasizes the importance of international coordination between health authorities during a pandemic in order to properly evaluate decisions made by foreign authorities.
Article
Public, Environmental & Occupational Health
Vageesh Jain, Paula Lorgelly
Summary: This study found that the pause in the use of the Oxford-AstraZeneca vaccine had minimal impact on subsequent vaccine uptake in European countries.
EUROPEAN JOURNAL OF PUBLIC HEALTH
(2022)
Article
Medicine, General & Internal
Norah S. Alhammad, Heba H. Milibary, Razan R. Baghdadi, Toleen M. Alawadi, Rawan E. Hudairy
Summary: This article reports on a case of morbilliform eruption in a 28-year-old female following COVID-19 vaccination, discussing its clinical and histopathological features. The patient showed significant improvement after treatment. The article emphasizes the importance of awareness for possible adverse reactions associated with COVID-19 vaccines.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Immunology
Mansour Tobaiqy, Katie MacLure, Hajer Elkout, Derek Stewart
Summary: Thrombotic adverse events, particularly with the Oxford-AstraZeneca vaccine, were rare but associated with fatal outcomes. Pulmonary embolism was significantly associated with a fatal outcome, with higher rates reported for Pfizer and Oxford-AstraZeneca vaccines.
Article
Medicine, General & Internal
Gie Ken-Dror, Pankaj Sharma
Summary: Blood group O is more prevalent among patients with VITT-CVT after ChAdOx1-S vaccination compared with unvaccinated cases, independent of well-established CVT risk factors. A larger dataset may be able to determine whether those of blood groups B and/or AB may be safely vaccinated with the low cost, readily available and easily transported ChAdOx1-S rather than adopting a complete ban.
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE
(2023)
Article
Biotechnology & Applied Microbiology
Endeshaw Chekol Abebe, Teklie Mengie Ayele, Zelalem Tilahun Muche, Awgichew Behaile T. Mariam, Nega Dagnaw Baye, Melaku Mekonnen Agidew, Tadesse Asmamaw Dejenie
Summary: This study aimed to evaluate and compare the adverse effects of Janssen and Oxford-AstraZeneca vaccines among vaccinated adults. The majority of participants reported at least one side effect after vaccination, with a significantly higher occurrence among recipients of the AstraZeneca vaccine. The main adverse symptoms in both vaccines included injection site pain, fever, fatigue, arthralgia, and myalgia. Participants who received the AstraZeneca vaccine also had a significantly higher total number of symptoms.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Ophthalmology
Meenakshi Sindhu, Ravi Kant Bamotra, Sukhdev Singh
Summary: We report a case of acute bilateral central serous chorioretinopathy (CSCR) in a young, otherwise healthy male with no associated risk factors after receiving the first dose of Covishield vaccine.
INDIAN JOURNAL OF OPHTHALMOLOGY
(2023)
